Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation
Tolterodine is a new competitive muscarinic receptor antagonist developed for the treatment of the unstable bladder. A total of 242 patients were enrolled in a multicenter, multinational, randomized, double-blind, placebo-controlled study conducted over a period of 4 weeks in patients with detrusor overactivity and symptoms of frequency, urgency, and urge incontinence. The objective of the study was to compare the efficacy and safety of tolterodine given at 1 or 2 mg b.i.d. versus placebo. At week 4 a statistically significant increase in the volume at first contraction (p = 0.030) and maximal cystometric capacity (p = 0.034) was only in the tolterodine 2 mg b.i.d. group. Tolterodine was safe and generally well tolerated. The incidence of dry mouth, as the most commonly reported adverse event, was only 9% and of mild to moderate intensity.
Unable to display preview. Download preview PDF.
- 1.Andersson K-E (1988) Current concepts in the treatment of disorders of micturition. Drugs 35: 477–494Google Scholar
- 2.Couillard DR, Webster GD (1995) Detrusor instability. Urol Clin North Am 22: 593–612Google Scholar
- 3.Kelleher CI, et al (1994) Antichoinergic therapy: the need for continued surveillance (abstract 59). Neurol Urdoyn 13: 4Google Scholar
- 4.Lockhart JL, Shessel F, Weinstein D, Politano VA (1982) Urodynamics in women with stress and urge incontinence. Urology 20: 333–336Google Scholar
- 5.Nilvebrant L, et al (1997) Tolterodine — a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci (in press)Google Scholar
- 6.Ouslander et al (1988) Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 140: 47–50Google Scholar
- 7.Thüroff J, et al (1991) Randomised, double-blind, multicentre trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 145: 813–817Google Scholar
- 8.Yarker YE, Goa KL, Fitton A (1995) Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6: 243–262Google Scholar